|
FRIDAY 30 NOVEMBER 2007
Welcome
Welcome to Miami
Eugene Schiff
Welcome to the meeting
Pierre Van Damme
Session 1 Opening and objectives
Chairs: Eugene Schiff, Robert Purcell
8h20
The epidemiology, the need for
an evidence-based decision making process
with regard to control of hepatitis A. Argentina 944 Kb(.pdf)
Angela Gentile
Session 2 Hepatitis A virus infection
Chairs: Eugene Schiff, Robert Purcell
8h50
Highlights in the discovery of the Hepatitis A Virus 4.1 Mb(.pdf)
Stephen Feinstone
9h10
Clinical manifestations of
Hepatitis A infection 168 Kb(.pdf)
Brian McMahon
Session 3 Epidemiology of hepatitis A
Chairs: Alessandro Zanetti, Daniel Shouval
9h30
Surveillance for acute Hepatitis A and the link to prevention 335 Kb(.pdf)
Annemarie Wasley
9h45
Evolution of global
Hepatitis A epidemiology 993 Kb(.pdf)
Craig Shapiro
10h05
Measurement of
burden of disease of Hepatitis A in Europe: Euro-hep.net
surveillance project 799 Kb(.pdf)
Paolo Bonanni
Session 4 Laboratory diagnosis and molecular epidemiology
Chairs: Alessandro Zanetti, Daniel Shouval
10h40
Diagnostics for control of Hepatitis A. What do we need and why? 166 Kb(.pdf)
Harold Margolis
Examples of molecular epidemiological studies:
Session 5 (A +B) Country and regional studies of hepatitis A epidemiology
Break out session (A)
Chairs: Jeffrey Mphahlele
13h30 Brazil 568 Kb(.pdf)
Claudia Lamarca Vitral
13h45
Mexico José
Santos
14h00
Saudi Arabia 739 Kb(.pdf) Haysam Tufenkeji
14h25 Italy 277 Kb(.pdf)
Alfonso Mele
14h40
Turkey 608 Kb(.pdf)
Meral A. Ciblak
14h55
South Africa 399 Kb(.pdf) Jefferey Mphahlele
Break out session (B)
Chairs: Beth Bell, Ian Gust
13h30
China 126 Kb(.pdf)
Zhi-Yi Xu
13h45
Korea 555 Kb(.pdf) Jong-Hyun Kim
14h00
Thailand 1.2 Mb(.pdf) Voranush
Chongsrisawat
14h25 India 351 Kb(.pdf)
Vidya Arankalle
14h40
Russia 147 Kb(.pdf)
Sergey Mukomolov
14h55
Ukraine 286 Kb(.pdf) Anna Moisseeva
Session 6 Hepatitis A vaccines
Chairs: Pierre Van Damme, Ron Dagan
15h30
Development of Hepatitis A vaccines 1.14 Mb(.pdf)
Ian Gust 15h50
Hepatitis A: Performance of the available vaccines 260 Kb(.pdf)
Koen Van Herck
Session 7 Prevention and control of hepatitis A infections
Chairs: Pierre Van Damme, Ron Dagan
16h10
Prevention effectiveness of current immunization strategies as
measured by disease/infection reduction 587 Kb(.pdf)
Beth P. Bell
16h40
Epidemiology and prevention
strategies for adults at increased risk for Hepatitis A. 315 Kb(.pdf)
John W. Ward
17h00
Hepatitis A vaccine versus immune globulin for postexposure
prophylaxis 167 Kb(.pdf)
John C. Victor
SATURDAY 1 DECEMBER 2007
Session 7 (continu): Prevention and control of hepatitis A infections
Chairs: Craig Shapiro, Steven Wiersma
8h00
Hepatitis A
prevention in travellers 1.3 Mb(.pdf)
Robert Steffen
Session 8 Vaccine financing and introduction of new vaccines
Chairs: Craig Shapiro, Steven Wiersma
8h30
Economics: Cost-effectiveness of options for hepatitis A
vaccination 372 Kb(.pdf)
Philippe Beutels9h00
A mathematical model of
Hepatitis A
transmission to indicate value of universal childhood immunization 232 Kb(.pdf)
Thierry Van Effelterre
9h20
Cost-effectiveness analysis of hepatitis A vaccination in Canada
using a dynamic model 301 Kb(.pdf)
Chris Bauch
9h40
Introduction of new vaccines: perspectives from PAHO's
Pro-Vac experience 549 Kb(.pdf)
Jon Kim Andrus
10h00
Challenges in introducing new vaccines: GAVI experiences 413 Kb(.pdf)
Susie Lee
Session 9 Country and regional examples of hepatitis A prevention
Chairs: Paolo Bonanni, Koen Van Herck
10h40
Argentina 460 Kb(.pdf) Marta N. Vacchino
10h55
The Netherlands 606 Kb(.pdf) Jim Van Steenbergen
11h10 Italy, Puglia 578 Kb(.pdf)
Roberta Pastore
11h25 Israel 213 Kb(.pdf) Ron Dagan
11h40 Spain, Catalonia 247 Kb(.pdf) Angela Dominguez
11h55 Australia
Philippe Beutels
13h45 Chile 515 Kb(.pdf)
Katia Abarca
14h00 Belarus 427 Kb(.pdf) Elena Fisenko
14h15 Russia 313 Kb(.pdf)
Vasily Akimkin, Anvar Rassouli
14h30 China 2.13 Mb(.pdf) Xiaofeng
Liang
Session 10 oral presentation of selected abstracts
Chairs: John Ward, Alfonso Mele
After the review of the submitted abstracts by the scientific
committee, one author per topic was invited for an oral
presentation.
Session 11 Round table discussion
Chairs: Blain Hollinger, Harold Margolis
Moderated Q&A session with panel of representatives from countries
that made a decision to introduce the vaccine nationwide. What went
into making such a decision ‘60
Session 12 Conclusions and future directions
Future of global prevention and control of hepatitis A infection:
Closing remarks
Pierre Van Damme
|
